Interest Expense is the amount reported by a company or individual as an expense for borrowed money. AbbVie's interest expense for the
three
months ended in Mar. 2026 was MXN -12,929 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was MXN-53,275 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. AbbVie's Operating Income for the
three
months ended in Mar. 2026 was MXN 85,367 Mil. AbbVie's Interest Expense for the
three
months ended in Mar. 2026 was MXN -12,929 Mil.
AbbVie's Interest Coverage for the quarter that ended in Mar. 2026 was 6.60.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
AbbVie (MEX:ABBV) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
AbbVie Interest Expense Historical Data
* Premium members only.
The historical data trend for AbbVie's Interest Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-53,275 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Expense of MXN-53,275 Mil mean?
AbbVie (MEX:ABBV) has a Interest Expense of MXN-53,275 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on AbbVie and its competitors.
Is AbbVie's Interest Expense too high?
AbbVie's current Interest Expense is MXN-53,275 Mil. Overall, AbbVie has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbbVie's Interest Expense compare to MRK and JNJ?
AbbVie's Interest Expense of MXN-53,275 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Drug Manufacturers company?
A good Interest Expense depends on the Drug Manufacturers industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on AbbVie and its competitors. AbbVie's current Interest Expense is MXN-53,275 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbbVie stock overvalued right now?
Based on GuruFocus' analysis, AbbVie (MEX:ABBV) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN3,572.08, compared to a current price of MXN4,402.62 — trading 23.3% above its estimated fair value. The current Interest Expense is MXN-53,275 Mil. AbbVie's overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For AbbVie (MEX:ABBV), the current Interest Expense is MXN-53,275 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AbbVie (MEX:ABBV) Overvalued in 2026?
Based on GuruFocus' analysis, AbbVie stock appears to be overvalued.
The current stock price of MXN4,402.62 is trading 23.3% above its estimated GF Value™ of MXN3,572.08.
GuruFocus considers AbbVie to be Modestly Overvalued.
Key valuation signals for MEX:ABBV:
Interest Expense: MXN-53,275 Mil
GF Value™: MXN3,572.08 vs. price of MXN4,402.62 (23.3% above fair value)
No single metric tells the full story. See the MEX:ABBV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
71GF Score
Get the complete analysis for MEX:ABBV
Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:ABBV has been successfully added to your 
